SCHEMBL6830366

SCHEMBL6830366

CCOC(=O)C#Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 3/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PTPN1 P18031 1/20 0.40
GSK3B P49841 1/20 0.40
MAOB P27338 1/20 0.40
EPHX2 P34913 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847106 0.86 RARB (0.50) MAPTALDH1A1KMT2AMEN1EPHX2
SCHEMBL2433672 0.82 APP (0.45) NPSR1MAPTALDH1A1KMT2AKDM4E
SCHEMBL854121 0.82 GABRP (0.48) MAPTALDH1A1PTPN1GSK3BEPHX2
SCHEMBL28747451 0.82 VCP (0.46) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL9935172 0.80 CA12 (0.50) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL852379 0.79 L3MBTL1 (0.44) MAPTALDH1A1KMT2AKDM4EGSK3B
SCHEMBL788820 0.79 APP (0.49) ALDH1A1GAA
SCHEMBL2300644 0.79 ACACB (0.44) MAPTALDH1A1
SCHEMBL11544791 0.79 ALDH1A1 (0.53) ALDH1A1
SCHEMBL853721 0.79 CDC7 (0.43) NPSR1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111285874-A RET inhibitors, pharmaceutical compositions thereof and uses thereof 广东东阳光药业有限公司 2020-06-16 CN disclosed
EP-1226108-A4 DIARYL-ENYNES NPS ALLELIX CORP (CA) 2004-06-16 EP disclosed
US-6579987-B2 Reducing an ester containing ene-yne conjugated, silane and aryl or heteroaryl functionality to an alcohol; bromination, amination, desilanation, coupling and deprotecting NPS ALLELIX CORPORATION (CA) 2003-06-17 US disclosed
US-20030092769-A1 DIARYL-ENYNES NPS ALLELIX CORPORATION (CA) 2003-05-15 US disclosed
US-6525085-B2 Treating neurological and neuropsychiatric disorders NPS ALLELIX CORP. (CA) 2003-02-25 US disclosed
US-20020169197-A1 Diaryl-enynes NPS ALLELIX CORP. 2002-11-14 US disclosed
EP-1226108-A1 DIARYL-ENYNES NPS Allelix Corp. (CA) 2002-07-31 EP disclosed
US-6426364-B1 NERVOUS SYSTEM OR PSYCHOLOGICAL DISORDERS NPS ALLELIX CORP. (CA) 2002-07-30 US disclosed
WO-2001032602-A1 DIARYL-ENYNES NPS ALLELIX CORP. (CA) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169197-A1 Diaryl-enynes CBR3, CNR1, NR3C2 NPSR1 82/4885MAPT 4189/4885ALDH1A1 2117/4885
US-20030092769-A1 DIARYL-ENYNES CBR3, CNR1, CBR1 NPSR1 81/4885MAPT 4186/4885ALDH1A1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.